Home Ingredients K2Quest® (Fermentation-Derived Vitamin K2 MK-7)
Bone HealthCardiovascularWomen's Health

K2Quest® (Fermentation-Derived Vitamin K2 MK-7)

Evidence Level
Strong
1 Clinical Trial
3 Documented Benefits
4/5 Evidence Score

K2Quest® (NutriScience Innovations) is a high-purity Vitamin K2 as menaquinone-7 (MK-7) produced through microbial fermentation — the long-chain form of K2 with the longest plasma half-life (~3 days vs. ~1 hour for MK-4) and highest bioavailability among all K2 forms. Vitamin K2 MK-7 activates both osteocalcin (directing calcium into bones) and matrix Gla protein (preventing calcium from depositing in arteries) — making it the critical link between calcium supplementation, bone density, and cardiovascular safety. K2Quest® also supports PMS symptom management through progesterone modulation.

Studied Dose 90–180 mcg/day MK-7 for bone and cardiovascular health; PMS: 90 mcg/day; 3-year RCT dose: 180 mcg/day; fermentation-derived MK-7 has ~72-hour plasma half-life enabling once-daily dosing
Active Compound Menaquinone-7 (MK-7) — K2Quest® by NutriScience Innovations; fermentation-derived Vitamin K2 in the all-trans configuration; typical dose 90–360 mcg/day

Benefits

Bone density and fracture risk reduction

Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones. A 3-year double-blind RCT confirmed MK-7 (180 mcg/day) significantly improved bone mineral density and bone strength markers vs. placebo in postmenopausal women, with the longest placebo-controlled bone study published for a K2 supplement.

Supported by Trial 1

Cardiovascular protection — preventing arterial calcification

Matrix Gla protein (MGP) is the body's primary inhibitor of vascular calcification — but it requires Vitamin K2 to become activated (carboxylated). Inadequate K2 leaves MGP inactive, allowing calcium to deposit in arterial walls, increasing arterial stiffness and cardiovascular risk. Clinical studies confirm MK-7 supplementation significantly reduces circulating inactive-MGP (a marker of arterial calcification risk) and improves arterial stiffness in adults.

Supported by Trial 1

PMS symptom management

Clinical research on MK-7 demonstrates reduction in PMS-associated symptoms including mood changes, cramps, and bloating — attributed to K2's role in progesterone receptor activation and modulation of prostaglandin pathways that drive menstrual cramping. This positions K2Quest® for women's health formulations combining bone, cardiovascular, and hormonal benefits.

Supported by Trial 1

Mechanism of action

1

Carboxylation of Gla-proteins: osteocalcin and MGP activation

Vitamin K2 serves as the essential cofactor for gamma-glutamyl carboxylase — the enzyme that carboxylates (activates) Gla-domain proteins including osteocalcin and matrix Gla protein (MGP). Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and calcium ions, anchoring them in bone matrix for density and strength. Carboxylated MGP actively chelates calcium ions in vessel walls and inhibits vascular smooth muscle calcification. Without adequate K2, both proteins remain inactive (undercarboxylated), resulting in bone loss AND arterial calcification — explaining the strong epidemiological association between K2 intake and both bone and cardiovascular health.

Clinical trials

1
MK-7 Vitamin K2 for Bone Mineral Density — 3-Year RCT
PubMed

Randomized, double-blind, placebo-controlled trial of MK-7 (180 µg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: bone mineral density (DXA at lumbar spine, femoral neck, hip), bone strength markers, vertebral fracture risk. (Knapen et al. 2013, Osteoporos Int)

244 healthy postmenopausal women. 3-year intervention.

MK-7 significantly preserved bone mineral density at lumbar spine (BMD +0.7%) and femoral neck vs placebo (which showed BMD decline of -1.3%). Bone strength markers (osteocalcin carboxylation status) improved. CRITICAL CONTEXT: this trial is the foundation of MK-7 bone health marketing. Pharmaceutical bisphosphonates (alendronate, zoledronate) and denosumab produce LARGER BMD increases (~3-7% over 3 years) and have direct fracture reduction evidence. MK-7 is a reasonable adjunctive bone health intervention for healthy postmenopausal women, NOT a substitute for established osteoporosis pharmacotherapy.

Side effects and drug interactions

Common Potential side effects

Excellent safety profile at 90–360 mcg/day
Well-tolerated in all clinical studies including the 3-year RCT
No upper tolerable intake level established by most regulatory agencies

Important Drug interactions

Warfarin (vitamin K antagonist) — MK-7 directly opposes warfarin's mechanism; AVOID if on warfarin therapy
Other anticoagulants — maintain consistent K2 intake and monitor clotting parameters
Broad-spectrum antibiotics — reduce intestinal K2 production; may need to increase supplemental K2

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…

Frequently asked questions about K2Quest® (Fermentation-Derived Vitamin K2 MK-7)

What is the recommended dosage of K2Quest® (Fermentation-Derived Vitamin K2 MK-7)?

The clinically studied dose for K2Quest® (Fermentation-Derived Vitamin K2 MK-7) is 90–180 mcg/day MK-7 for bone and cardiovascular health; PMS: 90 mcg/day; 3-year RCT dose: 180 mcg/day; fermentation-derived MK-7 has ~72-hour plasma half-life enabling once-daily dosing. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is K2Quest® (Fermentation-Derived Vitamin K2 MK-7) used for?

K2Quest® (Fermentation-Derived Vitamin K2 MK-7) is studied for bone density and fracture risk reduction, cardiovascular protection — preventing arterial calcification, pms symptom management. Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones.

Are there side effects from taking K2Quest® (Fermentation-Derived Vitamin K2 MK-7)?

Reported potential side effects may include: Excellent safety profile at 90–360 mcg/day Well-tolerated in all clinical studies including the 3-year RCT Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does K2Quest® (Fermentation-Derived Vitamin K2 MK-7) interact with medications?

Known drug interactions may include: Warfarin (vitamin K antagonist) — MK-7 directly opposes warfarin's mechanism; AVOID if on warfarin therapy Other anticoagulants — maintain consistent K2 intake and monitor clotting parameters Consult a pharmacist or healthcare provider if you take prescription medications.

Is K2Quest® (Fermentation-Derived Vitamin K2 MK-7) good for bone health?

Yes, K2Quest® (Fermentation-Derived Vitamin K2 MK-7) is researched for Bone Health support. Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones.